Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07852637) titled 'Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Samsung Medical Center
Condition:
Venous Thromboembolism
Active Cancer
Intervention:
Drug: edoxaban
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: November 1, 2026
Target Sample Size: 2300
Countries of Recruitment:
South Korea
To know more, visit https://clinicaltrials.gov/study/NCT07852637
Disclaimer: Cura...